Patient characteristics
| Patient characteristics . | HL patients, no. (%) . |
|---|---|
| All patients | 1474 (100) |
| Sex | |
| Male | 790 (53.6) |
| Female | 684 (46.4) |
| Age at start of treatment | |
| No older than 20 ya | 314 (21.3) |
| 21-25 y | 363 (24.6) |
| 26-30 y | 296 (20.1) |
| 31-35 y | 266 (18.0) |
| Older than 35 y | 235 (15.9) |
| Attained age at end of follow-up | |
| No older than 35 y | 244 (16.6) |
| 36-40 y | 214 (14.5) |
| 41-45 y | 221 (15.0) |
| 46-50 y | 247 (16.8) |
| 51-55 y | 252 (17.1) |
| Older than 55 years | 296 (20.1) |
| Treatment period | |
| Before 1974 | 416 (28.2) |
| 1974-1982 | 477 (32.4) |
| 1983-1995 | 581 (39.4) |
| Treatmentb | |
| RT only | 406 (27.5) |
| CT only | 71 (4.8) |
| RT + CT, anthracylines | 435 (29.5) |
| RT + CT, no anthracylines | 559 (37.9) |
| Unknown | 3 (0.2) |
| Radiotherapyc | |
| RT mediastinumd | 1241 (84.2) |
| RT PAO or inverted Y with spleene | 410 (27.8) |
| RT PAO or inverted Y without spleenf | 280 (19.0) |
| Type of chemotherapy | |
| MOPPg | 255 (23.9) |
| ABVDg | 38 (3.6) |
| MOPP/ABVg | 189 (17.7) |
| Other combined CTh | 496 (46.6) |
| Unknown | 87 (8.2) |
| Vital status at date of last contact | |
| Alive | 1017 (69.0) |
| Dead | 457 (31.0) |
| Follow-up interval | |
| 6-10 y | 197 (13.4) |
| 11-15 y | 322 (21.8) |
| 16-20 y | 292 (19.8) |
| 21-25 y | 268 (18.2) |
| 26-30 y | 200 (13.6) |
| More than 30 y | 195 (13.2) |
| Risk factorsi | |
| Smokingj | |
| Recent | 253 (17.2) |
| Ever | 675 (45.8) |
| Never | 541 (36.7) |
| Unknown | 258 (17.5) |
| Hypertension | |
| Yes | 147 (10.0) |
| No | 1292 (87.7) |
| Unknown | 35 (2.4) |
| Diabetes mellitus | |
| Yes | 73 (5.0) |
| No | 1381 (93.7) |
| Unknown | 20 (1.4) |
| Hypercholesterolemia | |
| Yes | 126 (8.5) |
| No | 1316 (89.3) |
| Unknown | 32 (2.2) |
| Patient characteristics . | HL patients, no. (%) . |
|---|---|
| All patients | 1474 (100) |
| Sex | |
| Male | 790 (53.6) |
| Female | 684 (46.4) |
| Age at start of treatment | |
| No older than 20 ya | 314 (21.3) |
| 21-25 y | 363 (24.6) |
| 26-30 y | 296 (20.1) |
| 31-35 y | 266 (18.0) |
| Older than 35 y | 235 (15.9) |
| Attained age at end of follow-up | |
| No older than 35 y | 244 (16.6) |
| 36-40 y | 214 (14.5) |
| 41-45 y | 221 (15.0) |
| 46-50 y | 247 (16.8) |
| 51-55 y | 252 (17.1) |
| Older than 55 years | 296 (20.1) |
| Treatment period | |
| Before 1974 | 416 (28.2) |
| 1974-1982 | 477 (32.4) |
| 1983-1995 | 581 (39.4) |
| Treatmentb | |
| RT only | 406 (27.5) |
| CT only | 71 (4.8) |
| RT + CT, anthracylines | 435 (29.5) |
| RT + CT, no anthracylines | 559 (37.9) |
| Unknown | 3 (0.2) |
| Radiotherapyc | |
| RT mediastinumd | 1241 (84.2) |
| RT PAO or inverted Y with spleene | 410 (27.8) |
| RT PAO or inverted Y without spleenf | 280 (19.0) |
| Type of chemotherapy | |
| MOPPg | 255 (23.9) |
| ABVDg | 38 (3.6) |
| MOPP/ABVg | 189 (17.7) |
| Other combined CTh | 496 (46.6) |
| Unknown | 87 (8.2) |
| Vital status at date of last contact | |
| Alive | 1017 (69.0) |
| Dead | 457 (31.0) |
| Follow-up interval | |
| 6-10 y | 197 (13.4) |
| 11-15 y | 322 (21.8) |
| 16-20 y | 292 (19.8) |
| 21-25 y | 268 (18.2) |
| 26-30 y | 200 (13.6) |
| More than 30 y | 195 (13.2) |
| Risk factorsi | |
| Smokingj | |
| Recent | 253 (17.2) |
| Ever | 675 (45.8) |
| Never | 541 (36.7) |
| Unknown | 258 (17.5) |
| Hypertension | |
| Yes | 147 (10.0) |
| No | 1292 (87.7) |
| Unknown | 35 (2.4) |
| Diabetes mellitus | |
| Yes | 73 (5.0) |
| No | 1381 (93.7) |
| Unknown | 20 (1.4) |
| Hypercholesterolemia | |
| Yes | 126 (8.5) |
| No | 1316 (89.3) |
| Unknown | 32 (2.2) |
HL indicates Hodgkin lymphoma; RT, radiotherapy; CT, chemotherapy; PAO, para-aortic lymph nodes; inverted Y, para-aortic and iliac lymph nodes; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; MOPP/ABV, mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine; EBVP, epirubicine, bleomycin, vinblastine, prednisone.
Patients (n = 111) were 16 years or younger at HL diagnosis.
Included primary and salvage therapies. RT includes all radiotherapy fields, not only mediastinal radiotherapy.
Describing the most frequently used radiation fields.
1114 during primary treatment.
Patients (n = 372) received RT to the mediastinum, para-aortic lymph nodes (or inverted Y), and spleen.
Patients (n = 240) received RT to both the mediastinum and the para-aortic lymph nodes (or inverted Y) without RT to the spleen.
No other cytostatic drugs.
Among those combinations, including MOPP (n = 167), MOPP/ABV (n = 51), ABVD (n = 73), and EBVP (n = 43).
Data from oncology records and general practitioners, not from screening on cardiovascular risk factors.
No mutually exclusive categories.